ClinicalTrials.gg
CompletedNCT00311389Updated Feb 14, 2012

A 12-Month Study to Evaluate the Efficacy and Safety of Once-Daily Instillation of Combination Glaucoma Therapy in Patients With Open-Angle Glaucoma or Ocular Hypertension

A Phase 3 interventional study of Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution and Latanoprost 0.005%/Timolol 0.005% ophthalmic solution in Glaucoma, Open-angle and Ocular Hypertension, sponsored by Alcon Research. Completed at 1 site in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-02-14.

Sponsored by Alcon Research (part of Alcon) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
408
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.

Enrollment
7th of 45
408 · median 135
Started
2003
with 2 others
Phase 3
16 of 46
none open now
Registered
8th of 46
by date
Lead sponsor
29 of 46
Alcon Research

Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 7th largest by enrollment of the 45 interventional ones that give a count, is one of 3 that started in 2003, is one of 16 in phase 3, and was the 8th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 116 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About travoprost

Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 83 Glaucoma, Open-Angle studies recruiting now, 64 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing travoprost in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the intraocular pressure(IOP)-lowering efficacy of a combination IOP-lowering therapy in patients with open-angle glaucoma or ocular hypertension.

03

Conditions studied

  • Glaucoma, Open-angle
  • Ocular Hypertension

Keywords

  • Glaucoma
  • POAG
  • OAG
  • OHT
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • As specified in protocol

Exclusion criteria

Exclusion Criteria:

  • As specified in protocol
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
408 participants (actual)

Study arms

  • Experimental
    Travoprost/Timolol

    1 drop in the affected eye(s) once daily in the morning for 12 months

    Drug: Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution

  • Active comparator
    Latanoprost/Timolol

    1 drop in the affected eye(s) once daily in the morning for 12 months

    Drug: Latanoprost 0.005%/Timolol 0.005% ophthalmic solution

Interventions

  • DrugTravoprost 0.004%/Timolol maleate 0.5% ophthalmic solution

    Drug page: Travoprost

    Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

  • DrugLatanoprost 0.005%/Timolol 0.005% ophthalmic solution

    Drug page: Latanoprost

    Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension

06

What researchers measure

Primary outcomes

  1. Mean Intraocular Pressure (IOP)

    Time frame: 12 months

07

Study locations

1 site
  • European Facilitiies
    Puurs, Belgium
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2003, a primary completion of Sep 2004 and a completion of Sep 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 4, 2006
First posted
Apr 6, 2006
Start
Jan 2003
Primary completionActual
Sep 2004
CompletionActual
Sep 2004
Last update
Feb 14, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00311389
Lead sponsor
Alcon Research
Responsible party
Sponsor
First posted
Apr 6, 2006
Start date
Jan 2003
Primary completion
Sep 2004
Completion
Sep 2004
Last update
Feb 14, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Travoprost

Start the discussion